Drug intelligence / Profile preview

TATX-03b

Development stage: Preclinical
Lead developer: Talem Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**TATX-03b** is a preclinical four-monoclonal-antibody cocktail developed by ImmunoPrecise Antibodies through its subsidiary Talem Therapeutics for the prevention and treatment of COVID-19. The cocktail comprises antibodies 2-A6, 21-F2, 22-F7, and 23-H7, which bind distinct non-overlapping epitopes on the SARS-CoV-2 spike glycoprotein to neutralize viral infection and reduce the likelihood of viral escape. TATX-03b showed prophylactic and therapeutic activity in Syrian hamster SARS-CoV-2 challenge studies and was reported to retain neutralizing activity against multiple SARS-CoV-2 variants, including Delta and Omicron sublineages.

Targets

BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)

Beyond the preview

Go deeper on TATX-03b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TATX-03b.

Explore the full profile